Related Experiment Videos
New, long-acting, potent bradykinin antagonists
F Lembeck1, T Griesbacher, M Eckhardt
1Department of Experimental and Clinical Pharmacology, University of Graz, Austria.
British Journal of Pharmacology
|February 1, 1991
Summary
Three novel bradykinin (BK) antagonists demonstrate potent and long-lasting inhibition of BK effects across multiple bioassays. These compounds show specificity for BK, offering potential as research tools and therapeutic agents.
Area of Science:
- Pharmacology
- Biochemistry
Background:
- Bradykinin (BK) plays a role in various physiological processes.
- Development of specific BK antagonists is crucial for research and therapy.
Purpose of the Study:
- To evaluate the efficacy and characteristics of three new BK antagonists.
- To compare their potency and duration of action with existing antagonists.
Main Methods:
- Testing of three novel BK antagonists (compounds I, II, III) in nine bioassay preparations.
- Assays included visceral smooth muscles, vasoconstriction, plasma protein extravasation, prostaglandin E2 release, bronchoconstriction, and C-fibre nociceptor stimulation.
- Comparison with a known antagonist (compound IV).
Main Results:
- Compounds I, II, and III exhibited a potency order of I > II > III >> IV.
- The new antagonists displayed long-acting effects, outlasting experimental duration in some assays.
- Inhibitory effects were specific to BK, with no impact on other tested agents.
- Minimal agonistic effects observed only at very high concentrations.
Conclusions:
- The novel BK antagonists possess high affinity and long-lasting receptor interaction, contributing to their prolonged action.
- Resistance to enzymatic degradation may also contribute to their duration of action.
- These antagonists are valuable tools for studying BK's pathophysiological roles and hold therapeutic potential.